<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05023720</url>
  </required_header>
  <id_info>
    <org_study_id>YShujun</org_study_id>
    <nct_id>NCT05023720</nct_id>
  </id_info>
  <brief_title>Real-World Effectiveness of Regorafenib in the Treatment of Patients With Metastatic Colorectal Cancer</brief_title>
  <official_title>Real-World Effectiveness of Regorafenib in the Treatment of Patients With Metastatic Colorectal Cancer-A Retrospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henan Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Real-World Effectiveness of Regorafenib in the Treatment of Patients with Metastatic&#xD;
      Colorectal Cancer- A Retrospective, Observational Study&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To analyze the real-world usage pattern, effectiveness and factors associated with the&#xD;
      effectiveness of regorafenib in the treatment of patients with metastatic colorectal cancer&#xD;
      (mCRC). This retrospective, observational study included clinicopathological and follow-up&#xD;
      data of patients with mCRC who were treated with regorafenib from June 2017 to September&#xD;
      2020. Patients with incomplete data were excluded. Overall survival (OS) stratified by&#xD;
      combination therapy with programmed cell death ligand-1 (PD-L1) inhibitors, chemotherapy and&#xD;
      regorafenib dose was calculated by Kaplan Meier method and log rank test. R software version&#xD;
      4.0 was used for the analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 20, 2021</start_date>
  <completion_date type="Anticipated">December 21, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 21, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The difference in overall survival between the two groups calculated by Kaplan-Meier</measure>
    <time_frame>2021.7-2021.12</time_frame>
    <description>Survival differences between the monotherapy and combination groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The difference of OS in patients receiving different doses of regorafenib</measure>
    <time_frame>2021.11-2021.12</time_frame>
    <description>In the real world, regorafenib was used in different dosages: 40mg,80mg,120mg,160mg,respectively. The difference in overall survival time of patients with different dosage was compared.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Regorafenib in combination with other drugs</measure>
    <time_frame>2021.7-2021.10</time_frame>
    <description>In the real world, regorafenib was used in combination with chemotherapy, immunotherapy or other drugs, and the frequency of occurrence of different conditions was analyzed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival differences among the patients with different clinical phenotypes and genotypes</measure>
    <time_frame>2021.7-2021.10</time_frame>
    <description>To compare the survival of patients with mCRC by gender, age, tumor site and other genotypes</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Regorafenib group</arm_group_label>
    <description>Patients were given only regorafenib orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Joint group</arm_group_label>
    <description>The patient was treated with regorafenib orally and in combination with other medications</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>nonintervention</intervention_name>
    <arm_group_label>Joint group</arm_group_label>
    <arm_group_label>Regorafenib group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with pathologically proven colorectal adenocarcinoma whose disease progressed&#xD;
        after two lines of antitumor therapy were treated with regorafenib alone or in combination.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        1. Inclusion Criteria:&#xD;
&#xD;
               1. Must be a pathologically proven colorectal adenocarcinoma&#xD;
&#xD;
               2. Must have been treated with regorafenib&#xD;
&#xD;
               3. Regorafenib must be used after two lines of standard antitumor therapy&#xD;
&#xD;
          2. Exclusion Criteria:&#xD;
&#xD;
               1. Application is less than one course of treatment with regorafenib&#xD;
&#xD;
               2. First - or second-line treatment with regorafenib&#xD;
&#xD;
               3. Patients with multiple primary cancers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shujun Yang</last_name>
    <role>Study Director</role>
    <affiliation>Henan Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shujun Yang, bachelor</last_name>
    <phone>13803869419</phone>
    <email>nkyang@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Henan cancer hosiptal</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shujun Yang, bachelor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 29, 2021</study_first_submitted>
  <study_first_submitted_qc>August 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2021</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henan Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Shujun Yang</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>metastatic colorectal cancer</keyword>
  <keyword>regorafenib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Clinical data of the patients</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>At any time</ipd_time_frame>
    <ipd_access_criteria>Research needs</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

